ライフサイエンスコーパス: clinical test

1 were retrospectively tested for HPV using a clinical test.

2 ally advance this method to become a routine clinical test.

3 prediction model based solely on nonimaging clinical tests.

4 and exemptions from prescription charges for clinical tests.

5 to-end solution for MPS-based experiments or clinical tests.

6 ful of plasma proteins are routinely used in clinical tests.

7 itating the delivery and deployment of novel clinical tests.

8 0 in most studies evaluating combinations of clinical tests.

9 integrated from both TCM practice and modern clinical tests.

10 res a clinical assessment often supported by clinical tests.

11 inical model, establishing the rationale for clinical testing.

12 parental virus and merits consideration for clinical testing.

13 it convenient for patients to participate in clinical testing.

14 Some of these therapies have advanced to clinical testing.

15 but most CDK inhibitors have failed rigorous clinical testing.

16 pplements," which may not require additional clinical testing.

17 the same as vaccines entering Phase 1 human clinical testing.

18 bilization of such protein aggregates are in clinical testing.

19 strategy for SCLC treatment, which warrants clinical testing.

20 o minimize it will be important steps before clinical testing.

21 re currently undergoing preclinical or early clinical testing.

22 should be taken forward for experimental or clinical testing.

23 latory drugs that are in the early stages of clinical testing.

24 critical quality attributes appropriate for clinical testing.

25 coding regions of the genome (the exome) for clinical testing.

26 man mHAs in numbers and potency adequate for clinical testing.

27 re identified in research projects or during clinical testing.

28 atients with CKD are available and ready for clinical testing.

29 pproved in 2006 and 2009 following extensive clinical testing.

30 sion that can be gradually incorporated into clinical testing.

31 to prevent relapse are in various phases of clinical testing.

32 ll-molecule inhibitors are reported to be in clinical testing.

33 ersion from MCI to AD compared with baseline clinical testing.

34 clinical management of patients referred for clinical testing.

35 mising polymer-drug conjugate progressing to clinical testing.

36 hies, and that EpoD could be a candidate for clinical testing.

37 should have significant influence on future clinical testing.

38 slational approach including preclinical and clinical testing.

39 ographic atrophy in both pre and early-phase clinical testing.

40 muli that contained no monocular cues and on clinical testing.

41 a specific kinase inhibitor already in human clinical testing.

42 nt CLL patients would improve outcome merits clinical testing.

43 e activity that is in phase II and phase III clinical testing.

44 utcomes and may not optimally translate into clinical testing.

45 th neurodevelopmental disorders referred for clinical testing.

46 latory therapy tools available for immediate clinical testing.

47 ibitor compound, MP-10, has recently entered clinical testing.

48 bitors uncovered in this study are ready for clinical testing.

49 sults to frozen samples for multiple-analyte clinical testing.

50 g/kg every 3 months was selected for further clinical testing.

51 e bench into developmental programmes before clinical testing.

52 n-derived Abs promising candidates for human clinical testing.

53 es that block this integrin are currently in clinical testing.

54 e, and test interval are needed for reliable clinical testing.

55 e tested in assays that are more amenable to clinical testing.

56 c treatment of cancer in humans and warrants clinical testing.

57 make this chemoimmunotherapy attractive for clinical testing.

58 approaches are undergoing further randomized clinical testing.

59 , preclinical proof of concept, and possible clinical testing.

60 entially in analyzing patient samples during clinical testing.

61 ents for diarrhea were identified in routine clinical testing.

62 anufacture, as well as their preclinical and clinical testing.

63 tibody-drug conjugates are now in late-phase clinical testing.

64 e (Porcn) are candidate anticancer agents in clinical testing.

65 genesis of cardiac arrest through systematic clinical testing.

66 esidual diagnostic specimens remaining after clinical testing.

67 nists are being carried forward into phase I clinical testing.

68 genome annotation, comparative genomics, and clinical testing.

69 arly-phase trials only to fail in late-stage clinical testing.

70 new tuberculosis vaccine candidates entering clinical testing.

71 Semaglutide is currently in phase 3 clinical testing.

72 ied viral pathogens in more samples than did clinical testing (30/90 versus 16/90; McNemar P = 0.001)

73 peutic effects in animal models and in early clinical testing ((90)Y-humanized PAM4 IgG, (90)Y-clivat

74 In clinical testing, Abs against PD-1 have resulted in psor

75 to turn these biomarkers into an applicable clinical test after large scale validation.

76 of predicting conversion to AD compared with clinical testing alone.

77 These results indicate that BEZ235 merits clinical testing, alone and in combination with other ag

78 e respiratory samples obtained after routine clinical testing and 27 matched liquid cultures).

79 ration of HER2-targeting agents brought into clinical testing and a renewed attempt to treat HER2-dri

80 cific antigen combinations for high-priority clinical testing and establishes a generalizable approac

81 n-1-amine, PF-4455242, which entered phase 1 clinical testing and has demonstrated target engagement

82 Although RTS,S has undergone extensive clinical testing and has progressed through phase III cl

83 decay engineering to design new formats for clinical testing and other fluorescence-based applicatio

84 cardiac arrest patients requires systematic clinical testing and regular follow-up to unmask the cau

85 Hence, there is a critical interplay between clinical testing and research leading to gene-disease as

86 Appropriate clinical testing and risk stratification are essential t

87 mportance of assessing a temporal window for clinical testing and thereby questioning the accuracy of

88 The development of biomarkers for clinical testing and validation can be facilitated by th

89 Lung function was evaluated by conventional clinical tests and by impulse oscillometry in female lat

90 summarize evidence regarding the accuracy of clinical tests and classification algorithms compared wi

91 summarize evidence regarding the accuracy of clinical tests and classification algorithms compared wi

92 measure provides an added value to existing clinical tests and encourages the maintenance of life su

93 ltiplexing power required for differentiated clinical tests and the growing field of personalized med

94 All had a myopathy by clinical evaluation, clinical testing, and biopsy.

95 Several bnMAbs are currently in clinical testing, and we offer perspectives on their use

96 al mutant FLT3 inhibitors that is undergoing clinical testing, and which is currently in late-stage c

97 Although several clinical tests are in use, none accurately distinguish b

98 evelopment is mentioned, results from recent clinical tests are summarized, and potential areas for i

99 he cell surface receptor cKit are undergoing clinical testing as a cell source for heart failure and

100 G and IC/anti-CTLA-4 should be developed for clinical testing as a potentially effective novel immuno

101 arious stages of preclinical and early phase clinical testing as potential anticancer drugs.

102 olate would not be diagnosed by the standard clinical tests, as Angola lacks the plasmid-borne capsul

103 anner, and the more potent bnMAbs will allow clinical testing at infusion doses that are practically

104 ents of T-tau and P-tau performed in routine clinical testing at the Clinical Neurochemistry Laborato

105 This article describes the clinical tests available for distinguishing aggressive f

106 Clinical tests based on primer-initiated amplification o

107 cology failures reached expensive late-stage clinical testing before being abandoned.

108 Several other JAK2 inhibitors have entered clinical testing, but none have been approved and many h

109 rimarily related to lack of easily available clinical testing, but other factors included the presenc

110 presence is often confirmed with an invasive clinical test called intramuscular electromyography (EMG

111 As no current clinical test can diagnose individuals at risk of develo

112 A battery of clinical tests can allow early identification of neuroco

113 wide, and the timely selection of the right clinical tests can have a significant impact on their su

114 In situations in which clinical testing cannot be performed or when uncertainty

115 A clinical testing cohort was used to gain a broader under

116 in time (aPTT) and prothrombin time (PT) are clinical tests commonly used to screen for coagulation-f

117 Under typical clinical testing conditions, increased forward scatter h

118 ective tool for verification of C. difficile clinical testing criteria and safe reduction of inflated

119 ighlight the importance of using appropriate clinical testing criteria.

120 ent de novo events were further evaluated in clinical-testing data from Children's Hospital Boston an

121 We assessed clinical testing dates, approved indications, and regula

122 The Mallett Unit is a clinical test designed to detect the fixation disparity

123 r locations designed to match those found in clinical testing environments.

124 It also showed that a blood-based clinical test for at-risk male infants and toddlers coul

125 Hybrid Capture 2 (hc2), a clinical test for carcinogenic human papillomavirus (HPV

126 difference (NPD), a well-established in vivo clinical test for cystic fibrosis, reflects transepithel

127 an test is marginal so that its utility as a clinical test for early diagnosis of IFI is questionable

128 no US Food and Drug Administration-approved clinical test for M. genitalium available in the United

129 probe-to-bone (PTB) test is a commonly used clinical test for osteomyelitis (OM), but its utility ha

130 We now validate a clinical test for urinary [TIMP-2].[IGFBP7] at a high-se

131 oriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders

132 tumorigenesis, and Notch antagonists are in clinical testing for application in cancer.

133 Clinical testing for BMPR2 mutations is available and ma

134 ardial infarction and are undergoing further clinical testing for cardiomyopathy.

135 potent CCR5 coreceptor antagonist that is in clinical testing for daily oral pre-exposure prophylaxis

136 ults with cirrhosis, suggesting that further clinical testing for HE is warranted.

137 reatments that are undergoing preclinical or clinical testing for hypertension treatment.

138 rationale for extending HDAC inhibitors into clinical testing for indications involving these organs.

139 notherapies currently in worldwide phase III clinical testing for melanoma are discussed.

140 receptor (EGFR)-targeted therapies, limited clinical testing for RAS pathway mutations has recently

141 I-A, is the only one to have been subject to clinical testing for the treatment of metastatic tumours

142 half-life, are also important factors in the clinical testing for this virus.

143 that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL

144 needed and suggest specific experimental and clinical tests for each major theory that might help to

145 ing the basis for development of noninvasive clinical tests for early cancer detection.

146 n the CT alone, which are ignored in current clinical tests for PI resistance, conferred PI resistanc

147 Most of the available clinical tests for prognosis of post-anoxic coma are inf

148 tumor-derived RNA in the blood are promising clinical tests for SI-NET.

149 colleagues report the performance of various clinical tests for the detection of mecC-harboring methi

150 ensitivity and specificity of laboratory and clinical tests for trachoma in the absence of a gold sta

151 sed on a combination of symptoms, signs, and clinical tests, given that any one of these alone would

152 targeting this protein that are amenable for clinical testing has been challenging.

153 Pre-clinical testing has contributed to the recent approval

154 Early prototype development and clinical testing have shown that a consumer digital came

155 Successes in randomized clinical testing have supported the growing appreciation

156 less likely to fail in the various stages of clinical testing, have fewer postapproval withdrawals, a

157 liable predictors of hepatic toxicity in non-clinical testing; however, mice are considered to be a s

158 l biases are generally not considered during clinical testing; however, we suggest that such biases m

159 and generates proof-of-concept for ARGX-111 clinical testing in MET-positive oncologic malignancies.

160 inical models provided the framework for its clinical testing in MM, which has already provided favor

161 he need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously tran

162 erated c-Met inhibitor, currently in Phase 3 clinical testing in non-small cell lung cancer patients.

163 reating metastatic TNBC and warrants further clinical testing in patients.

164 very, early drug development, and definitive clinical testing in pivotal trials.

165 findings offer a rational strategy to guide clinical testing in preidentified subsets of patients wh

166 stigational compound is currently in phase 1 clinical testing in subjects with hemophilia A or B.

167 to replace conventional long and costly pre-clinical testing in the new drug administration process.

168 ly focused approaches for gene discovery and clinical testing in the next few years.

169 een substantiated with their development and clinical testing in the treatment of cancer.

170 are unlikely to be exploitable for improving clinical tests in healthy populations.

171 riatal neurons and are supportive of ongoing clinical tests in Parkinson's disease patients.

172 re currently under intensive development and clinical testing) in individuals with DN and perhaps oth

173 bly in future applications of genomics-based clinical tests, in which the biological groups are by de

174 into the assay process during the period of clinical testing included software enhancements, improve

175 Clinical testing included visual acuity, visual fields,

176 scue was evaluated using non-invasive, human clinical testing, including fundus auto-fluorescence, op

177 al, a variety of anti-HIV genes have reached clinical testing, including gene-editing enzymes, protei

178 sting were pathogens not assessed by routine clinical tests, including rhinovirus/enterovirus, human

179 (bsAbs) on a large scale for preclinical and clinical testing is a challenging task.

180 ever received a BRAF inhibitor; confirmatory clinical testing is ongoing.

181 g MRR based malaria diagnostics suitable for clinical testing is the fact that MRR baseline fluctuati

182 However, in clinical testing, it has shown limited benefit in patien

183 As such priming is not detectable by current clinical tests, it is unknown to what extent this occurs

184 erences were found in questionnaires scores, clinical tests, IVCM variables between therapy groups.

185 Interpretations are submitted by clinical testing laboratories, research laboratories, lo

186 ques, and extensive bench, pre-clinical, and clinical testing, lead failure (LF) remains the Achilles

187 ion discrepancies between patient report and clinical testing may be owing to home lighting may initi

188 ed for a minority of ill persons and routine clinical tests may not identify H3N2v virus, the count o

189 daptive strategies, in addition to the usual clinical tests, may provide a better insight into the im

190 th period, including whole genome sequences; clinical tests, metabolomes, proteomes, and microbiomes

191 HPLC, followed by direct sequencing using a clinical test of 121 with no definite mutation (plus con

192 auditory nerve fibers; however, there is no clinical test of this synaptopathy in humans.

193 ion and memory performance (as measured by a clinical test of verbal memory retention).

194 of mutations in this disease, the results of clinical testing of 699 advanced melanoma patients using

195 Clinical testing of a human IgG1 anti-CD27 Ab, varliluma

196 we demonstrate the technical development and clinical testing of a novel electronics enabled microflu

197 ility genes at once, suggesting that routine clinical testing of all incidence cases should be consid

198 th melanoma providing a strong rationale for clinical testing of alternative dosing regimens.

199 Results provide a rationale for broader clinical testing of AT1R-targeted molecular imaging.

200 to the identification, characterization, and clinical testing of ataluren, a new therapeutic with the

201 tion and presents a strong rationale for the clinical testing of combination MEK and PI3K targeted th

202 efficacious in these models, indicating that clinical testing of combinations of BCR-ABL kinase inhib

203 Our findings strongly support the clinical testing of combined hormone antagonist-low-leve

204 Further clinical testing of DENVax in different age groups and i

205 We initiated clinical testing of engineered T cells expressing an aff

206 provide rationale and practical platform for clinical testing of expanded and activated NK cells for

207 acute lymphoblastic leukemia (T-ALL) led to clinical testing of gamma-secretase inhibitors (GSIs) th

208 hese results provide compelling evidence for clinical testing of IMiDs alone and in combination with

209 Phase I clinical testing of inhibition of Janus kinase 2, active

210 tial as a non-human animal model for the pre-clinical testing of iNKT-stimulating glycolipids.

211 enhanced activity and to support the future clinical testing of intratumoral administration of immun

212 In summary, our results support the clinical testing of lymphodepletion and PD-1/PD-L1 block

213 These results warrant further clinical testing of META060 for its therapeutic potentia

214 tients with acute diarrhea have included the clinical testing of modifications to the standard oral r

215 he feasibility for using challenge models in clinical testing of new disease intervention strategies.

216 Pharmaceutical research requires pre-clinical testing of new therapeutics using both in-vitro

217 design, and a mechanistic rationale for the clinical testing of nonviral miRNA mimetics.

218 with conventional screening and monotherapy clinical testing of novel agents.

219 ertaken into the development and preliminary clinical testing of novel technologies including robotic

220 It set the stage for clinical testing of novel therapeutic strategies, such a

221 ce and risk, consideration might be given to clinical testing of PALB2 by complete genomic sequencing

222 These experiments support the clinical testing of pDNA vaccine candidates that may ult

223 e findings may support the rationale for the clinical testing of peripherally restricted CB1R antagon

224 Our findings support the clinical testing of PKC412 for treatment of mutant PDGFR

225 nt method for high-content screening and pre-clinical testing of potential STAT3 inhibitors in live c

226 ity of PR-171 and provide validation for the clinical testing of PR-171 in the treatment of hematolog

227 This assay/system performed well in clinical testing of regular seasonal influenza virus sub

228 This study establishes a foundation for clinical testing of sequential fractionated radiation fo

229 ation and provide a strong rationale for the clinical testing of TGF-beta signaling blockade to enhan

230 Based on these findings, clinical testing of the BIBW2992/rapamycin combination i

231 based on laboratory hypotheses, but without clinical testing of the hypotheses to show utility for t

232 rant further development and preclinical and clinical testing of the next generation of candidate MAP

233 provide a strong rationale for extending the clinical testing of the novel antimyeloma agent I-BET762

234 e present work describes the development and clinical testing of the paper-based biosensor that measu

235 pments lie mostly in the lessons learnt from clinical testing of these approaches.

236 These results therefore support clinical testing of this noninvasive-targeted drug deliv

237 CD33-directed antitumor activity and support clinical testing of this novel therapeutic in patients w

238 regulators and provides a rational basis for clinical testing of this therapeutic approach.

239 uses and temozolomide, and should propel the clinical testing of this therapy approach in patients wi

240 These studies form the basis for further clinical testing of TORC1/2 inhibitors in MM.

241 otential of more pragmatic approaches to the clinical testing of vaccine candidates, the field has pr

242 targeting of CSC prompts a new paradigm for clinical testing of VS-5584: clinical trials designed wi

243 Clinical tests of micronutrient levels from whole blood

244 een use of total B12 or holoTC as first-line clinical tests of vitamin B12 status.

245 arrying a SPRED1 mutation identified through clinical testing participated with their families in a g

246 D NGS panel tests, we analyzed data from all clinical tests performed at the Emory Genetics Laborator

247 Developing a clinical test predicting impending conversion to NV-ARMD

248 er of drug candidates and accelerate the pre-clinical testing process subject to animal testing upon

249 field (VF) values for children using common clinical test protocols for kinetic and static perimetry

250 The clinical tests provide evidence supporting seven pathway

251 stimation of CA activity in erythrocytes for clinical testing purposes.

252 -2-family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anti

253 -2 family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anti

254 Clinical testing reliability was compared between expert

255 iants in genes associated with CPVT from WES clinical testing represent disease-associated biomarkers

256 Using clinical test results from hospital admitted patients we

257 Thus, deficits in specific clinical test results were directly associated with loca

258 nts, thus facilitating the interpretation of clinical test results.

259 p = 0.0000, 0.037) than controls but similar clinical tests results (p > 0.05).

260 For the clinical test-retest imaging study, 10 patients with cer

261 However, clinical testing revealed a high incidence of duplicatio

262 tion of 120 sequential samples submitted for clinical testing revealed a variety of silent and amino

263 All subjects underwent clinical tests (Schirmer I and break-up time), in vivo c

264 ust be thoroughly deciphered and appropriate clinical tests selected to follow disease progression an

265 ned from finger prick (Theranos) and 2 major clinical testing services that require standard venipunc

266 ere compared with three test set conditions: clinical test set reading with prior images, laboratory

267 Clinical testing showed 95% sensitivity for influenza A

268 imaging, FDG PET, and CSF data with routine clinical tests significantly increased the accuracy of p

269 Often, high-sensitivity, point-of-care (POC) clinical tests, such as HIV viral load, require large vo

270 as testified by the number of candidates in clinical testing that unselectively target both PARP-1 a

271 There are no available clinical tests that can accurately predict peanut allerg

272 Clinical tests that evaluate the sense of smell face two

273 owth conditions and LB rich medium, and from clinical tests that identify V.cholerae.

274 elf, experimental medicine, and larger-scale clinical testing-there are specific needs for academic p

275 Because DOTATOC has undergone extensive clinical testing, this human reporter system has the pot

276 ugh ethyl pyruvate has undergone early-phase clinical testing, this was done without consideration of

277 These results can guide development of a clinical test to reveal this previously unknown form of

278 development strategies and outcomes of their clinical testing to date.

279 rate reactions in the same assay for routine clinical testing to detect influenza A and B viruses and

280 ROS and MAP) or biennial (ACT) cognitive and clinical testing to identify incident cases of dementia

281 man study groups and is now undergoing wider clinical testing to secure FDA approval for general use.

282 There are no specific laboratory or clinical tests to 'rule in' or 'rule out' the diagnosis.

283 iopurine S-methyltransferase are commonplace clinical tests to reduce hematologic problems associated

284 compounds transition from discovery, through clinical testing, to drugs.

285 The need for decentralized clinical tests together with the concept of time and cos

286 iews the strengths and limitations of common clinical tests used for the diagnosis of myocarditis, wi

287 multiple genes in a single disease-targeted clinical test using next generation sequencing.

288 positive negative controls in HP and CAP/CTM clinical testing was <0.5% over 6 to 7 months of testing

289 nce of weekly home monitoring over 6-monthly clinical testing was retained even when home monitoring

290 blish the effectiveness of the paradigm as a clinical test, we assessed if radial deformation hyperac

291 ord pathology more closely than conventional clinical tests, we explored the potential for spinal mag

292 tatic uveal melanoma did not warrant further clinical testing when assessed by ORR, although minor tu

293 rmore, this SNP could help resolve equivocal clinical tests where plasma MMA values have been used to

294 models, extended safety studies and further clinical testing will be required before the full therap

295 In the future clinical tests will be used for noninvasive diagnosis an

296 The FLC assay is a simple, widely available clinical test with similar prognostic utility as routine

297 ible loss of visual function in LHON support clinical testing with mutated G11778A mitochondrial DNA

298 ate the advancement of promising projects to clinical testing with the contributions of multidiscipli

299 32765) is the most advanced BTK inhibitor in clinical testing, with ongoing phase III clinical trials

300 Residual serum from the next ordered clinical test (within 12 hrs) was retrieved, frozen, and